PACS Raises Guidance, Yet Stock Drops on Regulatory Fears

PACS Group Inc (PACS) reported second-quarter 2026 results on August 5, 2026. The company delivered a strong financial performance, with revenue beating analyst estimates by $20 million and Non-GAAP EPS exceeding expectations by $0.07. Reflecting this momentum, management raised full-year Adjusted EBITDA and revenue guidance, signaling confidence in sustained operational growth and successful integration of recent acquisitions.

Revenue

The total revenue of PACS increased by 9.1% to $1.43 billion in 2026 Q2, up from $1.31 billion in 2025 Q2. On a same-store basis, which includes the 284 skilled nursing facilities operated by the Company as of the beginning of 2025, SNF revenue increased 5.8% compared to the prior-year period. Patient and resident service revenue contributed $1.43 billion, while other revenues accounted for $501,000, bringing the Total Revenue to $1.43 billion.

Earnings/Net Income

PACS's EPS rose 45.5% to $0.48 in 2026 Q2 from $0.33 in 2025 Q2, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $76.35 million in 2026 Q2, marking 49.8% growth from $50.97 million in 2025 Q2. The Company has sustained profitability for 4 years over the corresponding fiscal quarter, reflecting stable business performance. The significant year-over-year improvement in both EPS and net income demonstrates robust operational efficiency and effective cost management.

Price Action

The stock price of PACS has edged up 0.18% during the latest trading day, has dropped 4.58% during the most recent full trading week, and has edged up 0.74% month-to-date.

Post-Earnings Price Action Review

Market reaction to PACS's second-quarter results has been mixed, reflecting the interplay between strong fundamental performance and broader market sentiment. While the stock edged up 0.18% on the latest trading day, indicating some immediate investor interest, it experienced a 4.58% decline over the most recent full trading week, suggesting short-term profit-taking or cautious positioning following the earnings release. However, the positive month-to-date change of 0.74% implies that underlying support remains intact as investors digest the raised guidance and operational highlights.

CEO Commentary

Jason Murray, PACS Chief Executive Officer, emphasized that second-quarter results demonstrated the platform’s strength and exceptional local execution, delivering significant growth in revenue, net income, occupancy, and skilled mix while improving quality outcomes. He highlighted strategic expansion through the Eduro transaction, which adds 34 well-positioned facilities in Texas and other markets. Murray expressed confidence in the business’s momentum, citing the proven operating model and experienced leadership team as drivers for enhancing care and supporting teams. He concluded that these factors, combined with disciplined expansion, create meaningful opportunities for long-term growth and value creation as the company enters the second half of the year.

Guidance

PACS Group, Inc. raised its full-year 2026 Adjusted EBITDA guidance to a range of $640 million to $660 million, up from the previous $605 million to $625 million, representing approximately 29% growth at the midpoint over 2025. Revenue guidance was also increased to $5.75 billion to $5.85 billion, previously $5.65 billion to $5.75 billion. The updated outlook includes modest contributions from the 20 Eduro Texas facilities closed on August 1, 2026, but excludes remaining Eduro facilities not yet closed or any future acquisitions. Management noted a robust acquisition pipeline and remains actively evaluating transactions that align with strategic, operational, and financial criteria to continue scaling the platform.

Additional News

PACS Group continues to navigate a complex landscape marked by both strategic expansion and regulatory scrutiny. Recent developments highlight ongoing investigations by the Department of Justice and the SEC, alongside unresolved internal control weaknesses that pose potential risks to the company's operational stability. In response to these challenges and to support shareholder value, the company announced a new share repurchase authorization. Simultaneously, PACS is actively pursuing its growth strategy through acquisitions, specifically the recent closing of the Eduro transaction in Texas, which adds 34 facilities to its portfolio. Management maintains that these strategic moves, combined with a robust acquisition pipeline, will drive long-term value creation despite the current regulatory headwinds and focus on strengthening internal governance structures.